Biomics Biopharma (ASX:BBM) Debt-to-Revenue : 0.00 (As of . 20)

View and export this data going back to 2017. Start your Free Trial

What is Biomics Biopharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Biomics Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was A$0.00 Mil. Biomics Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was A$0.00 Mil. Biomics Biopharma's annualized Revenue for the quarter that ended in . 20 was A$0.00 Mil.

Biomics Biopharma Debt-to-Revenue Historical Data

The historical data trend for Biomics Biopharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomics Biopharma Debt-to-Revenue Chart

Biomics Biopharma Annual Data

Trend

Debt-to-Revenue

Biomics Biopharma Semi-Annual Data

Debt-to-Revenue

Competitive Comparison of Biomics Biopharma's Debt-to-Revenue

For the Biotechnology subindustry, Biomics Biopharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomics Biopharma's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomics Biopharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biomics Biopharma's Debt-to-Revenue falls into.

Biomics Biopharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Biomics Biopharma's Debt-to-Revenue for the fiscal year that ended in . 20 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(	+	)	/	N/A
	=	N/A

Biomics Biopharma's annualized Debt-to-Revenue for the quarter that ended in . 20 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(	+	)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is one times the quarterly (. 20) Revenue data.

Biomics Biopharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biomics Biopharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomics Biopharma (ASX:BBM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomics Biopharma Ltd (ASX:BBM) » Definitions » Debt-to-Revenue

Comparable Companies

ASX:G88 ASX:ELS ASX:BHD ASX:IBX ASX:ZEN ASX:OLI ASX:KPG ASX:CAN ASX:MPW ASX:CQG ASX:OCA

Traded in Other Exchanges

N/A

Address

1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000

Website

http://www.biomics.com

Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.

Biomics Biopharma (ASX:BBM) Headlines

No Headlines